PriceTargets.com logo

NASDAQ:PLXP - PLx Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.00
  • Forecasted Upside: 764.20 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$2.43 As of 06/30/2022 01:00 AM ET
▲ +0.18 (8.00%)

This chart shows the closing price for PLXP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PLx Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PLXP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PLXP

Analyst Price Target is $21.00
▲ +764.20% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for PLx Pharma in the last 3 months. The average price target is $21.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 764.20% upside from the last price of $2.43.

This chart shows the closing price for PLXP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in PLx Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/6/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/31/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/14/2022Raymond JamesLower Price TargetOutperform$14.00 ➝ $12.00High
12/7/2021Raymond JamesUpgradeMarket Perform ➝ Outperform$14.00High
11/1/2021JMP SecuritiesReiterated RatingBuy$21.00Low
9/21/2021BWS FinancialInitiated CoverageBuy$29.00High
8/20/2021JMP SecuritiesReiterated RatingBuy$21.00High
7/20/2021JMP SecuritiesBoost Price TargetOutperform$12.00 ➝ $21.00High
7/20/2021OppenheimerReiterated RatingBuy$22.00High
4/9/2021OppenheimerInitiated CoverageOutperform$20.00High
3/1/2021JMP SecuritiesBoost Price TargetOutperform$9.00 ➝ $12.00Low
8/14/2020Raymond JamesReiterated RatingHold ➝ HoldLow
5/18/2020JMP SecuritiesInitiated CoverageOutperformMedium
4/12/2019Janney Montgomery ScottInitiated CoverageBuyMedium
3/14/2019JMP SecuritiesInitiated CoverageOutperformHigh
1/14/2019Raymond JamesDowngradeOutperform ➝ Market PerformHigh
3/26/2018Janney Montgomery ScottDowngradeBuy ➝ Neutral$14.00Low
1/19/2018Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$14.00High
8/1/2017Redburn PartnersUpgradeOutperformLow
7/31/2017UBS GroupUpgradeMarket Perform ➝ Outperform$12.00High
(Data available from 7/1/2017 forward)

News Sentiment Rating

0.61 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/2/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/1/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/3/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/2/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/2/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
6/1/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/1/2022

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

PLx Pharma logo
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.
Read More

Today's Range

Now: $2.43
Low: $2.18
High: $2.43

50 Day Range

MA: $2.53
Low: $1.90
High: $3.51

52 Week Range

Now: $2.43
Low: $1.81
High: $21.50

Volume

162,899 shs

Average Volume

225,724 shs

Market Capitalization

$66.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.35

Frequently Asked Questions

What sell-side analysts currently cover shares of PLx Pharma?

The following Wall Street analysts have issued stock ratings on PLx Pharma in the last twelve months: BWS Financial, JMP Securities, Oppenheimer Holdings Inc., and Raymond James.
View the latest analyst ratings for PLXP.

What is the current price target for PLx Pharma?

0 Wall Street analysts have set twelve-month price targets for PLx Pharma in the last year. Their average twelve-month price target is $21.00, suggesting a possible upside of 764.2%.
View the latest price targets for PLXP.

What is the current consensus analyst rating for PLx Pharma?

PLx Pharma currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PLXP will outperform the market and that investors should add to their positions of PLx Pharma.
View the latest ratings for PLXP.

How do I contact PLx Pharma's investor relations team?

PLx Pharma's physical mailing address is 9 Fishers Lane Suite E, Sparta NJ, 07871. The biotechnology company's listed phone number is (973) 409-6541 and its investor relations email address is [email protected] The official website for PLx Pharma is www.plxpharma.com. Learn More about contacing PLx Pharma investor relations.